Drugs Made In America Acquisition Corp. SEC filings DMAA
Drugs Made In America Acquisition Corp. has 80 filings in SEC EDGAR's recent list, going back to Aug 1, 2024. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (material agreement, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 14, 2026 | Apr 27, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2026 | Mar 27, 2026 |
Showing 2 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- DMAA (Nasdaq), DMAAR (Nasdaq), DMAAU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2028614
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Source: SEC EDGAR filings. This is company-reported data, not investment advice.